Urogen Pharma: Submits FDA application for bladder cancer gel, shares jump

UroGen Pharma

12/11/2019 18:48

** U.S.-listed shares of drug developer  URGN.O  up 14.7% to
hit its highest level in about 1-1/2 months of $27.78 
    ** The Israel-based co announced submission of application
for FDA approval of UGN-101, a gel targeting a form of bladder
cancer  urn:newsml:reuters.com:*:nBwbpdxkRa
    ** Co expects FDA approval and drug launch by H1 of 2020 
    ** URGN also reports smaller-than-expected Q3 net loss per
share  urn:newsml:reuters.com:*:nL4N27S3NC
    ** Results come a day after co announced licensing agreement
with drug developer Agenus  AGEN.O  to develop and commercialize
drugs targeting urinary tract cancers  urn:newsml:reuters.com:*:nNRAa6xolc
    ** Brokerage Cowen called the deal positive for URGN's drug
development
    ** Stock down 35.5% YTD, as of Monday's close

 (Reporting by Ruhi Soni)
 ((Ruhi.Soni@thomsonreuters.com;))